Jiangsu Hengrui Pharmaceuticals (known as Hengrui Pharma) has announced the launch of Luzsana Biotechnology, a purpose-driven company focused on delivering medicines that are available, accessible and affordable to more people around the globe.
Luzsana, which is now a wholly-owned subsidiary of Hengrui Pharma — one of China's largest drugmakers — is a global development and commercialization biotech with access to Hengrui's world-class pipeline of more than 250 clinical studies in areas of high unmet medical need, such as oncology, cardiovascular, metabolic/diabetes, pain management, immunology and liver and renal disease. The company will inherit a pipeline from Hengrui that includes 11 high-potential oncology and non-oncology programs that span all stages of development from preclinical to phase 3, which it intends to further diversify over time.
With locations in Princeton, New Jersey, Basel, Switzerland, and Tokyo, Japan, Luzsana is stacked with industry veterans, headed by CEO Scott Filosi and CMO Joseph Eid.
"We believe the most effective medicines are ones that people can use. That's why we won't rest until we get our medicines into the hands of those who need them most — no matter their geography or socioeconomic status," said Filosi.
Luzsana plans to share further details about its oncology pipeline at the 2022 ASCO Annual Meeting in June.